Skip to main content

Table 1 Summary table on vaccine efficacy assumptions for HPV-related cervical cancer

From: Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland

Vaccine assumptionsHPV 16HPV 18HPV 31/33/45/52/58
Vaccine efficacy for preventing cervical HPV16/18/31/33/45/52/58 infections:
 Malea0.4110.6210.411
 Femaleb0.760.9630.76
Degree of protection of the vaccine against cervical HPV16/18 infections becoming persistent0.9880.9840.988
Degree of protection of the vaccine against HPV16/18-related CIN0.97910.979
  1. aPreventing male genital infections through male vaccination is assumed to prevent transmission of genital infections to females
  2. bPreventing female genital infections through vaccination is assumed to prevent transmission of genital infections to males
  3. Source: Giuliano et al. (2011) [33] for males and Elbasha and Dasbach [30] for females
\